Shane Ward Biography and Net Worth

Mr. Ward joined Cidara in 2021 as Chief Legal Officer and was appointed Chief Operating Officer in 2022. He has more than 25 years of biopharmaceutical industry legal, operations, strategy, and finance experience. In his current role, he is responsible for a range of Cidara's corporate functions including Legal, IP, Healthcare Compliance, Technical Operations, Quality, and IT. As Corporate Secretary, he also coordinates board and committee activities and oversees corporate governance. Prior to joining us, Mr. Ward was Chief Legal and Strategy Officer for Bellicum Pharmaceuticals, a clinical-stage cell therapy company developing controllable CAR-T products for the treatment of solid tumor cancers. He previously held leadership roles with commercial and development-stage biotechnology and pharmaceutical companies including Gilead Sciences, Human Genome Sciences, Dynavax, and Abbott. He began his legal career in the FDA regulatory practice group of Sidley Austin, an international law firm. Mr. Ward holds an M.B.A. from Cornell University, a J.D. from Georgetown University, and a B.A. from the University of Virginia.

What is Shane Ward's net worth?: The estimated net worth of Shane Ward is at least $3.24 million as of March 11th, 2025. Mr. Ward owns 14,674 shares of Cidara Therapeutics stock worth more than $3,235,617 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Ward may own. Additionally, Mr. Ward receives a salary of $464,540.00 as COO at Cidara Therapeutics. Learn More about Shane Ward's net worth.
How old is Shane Ward?: Mr. Ward is currently 49 years old. There are 5 older executives and no younger executives at Cidara Therapeutics. The oldest executive at Cidara Therapeutics is Dr. Jeffrey L. Stein Ph.D., President, CEO & Executive Director, who is 69 years old. Learn More on Shane Ward's age.
What is Shane Ward's salary?: As the COO of Cidara Therapeutics, Inc., Mr. Ward earns $464,540.00 per year. There are 4 executives that earn more than Mr. Ward. The highest earning executive at Cidara Therapeutics is Dr. Leslie Tari Ph.D., Chief Scientific Officer, who commands a salary of $845,100.00 per year. Learn More on Shane Ward's salary.
How do I contact Shane Ward?: The corporate mailing address for Mr. Ward and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]. Learn More on Shane Ward's contact information.
Has Shane Ward been buying or selling shares of Cidara Therapeutics?: Shane Ward has not been actively trading shares of Cidara Therapeutics during the last ninety days. Most recently, Shane Ward sold 1,664 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $21.96, for a transaction totalling $36,541.44. Following the completion of the sale, the chief operating officer now directly owns 14,674 shares of the company's stock, valued at $322,241.04. Learn More on Shane Ward's trading history.
Who are Cidara Therapeutics' active insiders?: Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Nicole Davarpanah (Insider), Timothy Franson (Director), Brady Johnson (VP), Jessica Oien (General Counsel), Preetam Shah (CFO), Jeffrey Stein (CEO), Leslie Tari (Insider), and Shane Ward (COO). Learn More on Cidara Therapeutics' active insiders.
Are insiders buying or selling shares of Cidara Therapeutics?: In the last twelve months, Cidara Therapeutics insiders bought shares 1 times. They purchased a total of 2,272,727 shares worth more than $99,999,988.00. In the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 3,911 shares worth more than $105,272.16. The most recent insider tranaction occured on September, 11th when insider Nicole Negar Davarpanah sold 474 shares worth more than $29,795.64. Insiders at Cidara Therapeutics own 3.9% of the company. Learn More about insider trades at Cidara Therapeutics.
Information on this page was last updated on 9/11/2025.

Shane Ward Insider Trading History at Cidara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2025	Sell	1,664	$21.96	$36,541.44	14,674
3/11/2024	Sell	1,023	$13.40	$13,708.20	9,938
3/13/2023	Sell	216	$30.60	$6,609.60	4,228

Shane Ward Buying and Selling Activity at Cidara Therapeutics

Cidara Therapeutics Company Overview

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Today's Range

Now: $220.50

$219.86

$220.69

50 Day Range

MA: $137.53

$90.50

$220.74

2 Week Range

Now: $220.50

$15.22

$221.20

Volume

453,521 shs

Average Volume

2,245,477 shs

Market Capitalization

$6.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Shane Ward Biography and Net Worth

What is Shane Ward's net worth?

How old is Shane Ward?

What is Shane Ward's salary?

How do I contact Shane Ward?

Has Shane Ward been buying or selling shares of Cidara Therapeutics?

Who are Cidara Therapeutics' active insiders?

Are insiders buying or selling shares of Cidara Therapeutics?